Research Reports

Key takeaways

CEO Yuval Cohen's annual base salary is set at $673,625 with a target bonus of 60% under a two-year agreement expiring April 15, 2028.

CFO Sean Moran's annual base salary is set at $501,273 with a target bonus of 40% under a two-year agreement expiring April 15, 2028.

CEO severance includes 12 months salary (24 months during Change in Control) plus 12-24 months COBRA reimbursement depending on timing.

CFO severance includes 12 months salary (18 months during Change in Control) plus 12-18 months COBRA reimbursement depending on timing.

Both executives are subject to 6-month non-compete and 12-month non-solicitation covenants following employment cessation.

Full analysis

Corbus Pharmaceuticals Holdings, Inc. formalized amended employment agreements with its two named executive officers, CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026. The agreements replace prior employment arrangements and establish fixed two-year terms expiring April 15, 2028. Compensation terms for Dr. Cohen include an annual base salary of $673,625 and a target bonus of 60%, while Mr. Moran receives a base salary of $501,273 with a target bonus of 40%. Both agreements contain standard confidentiality, assignment of inventions, non-compete, and non-solicitation provisions. Severance terms differentiate between standard termination scenarios and Change in Control (CIC) events, with the CEO eligible for 24 months salary and double-target bonus in a CIC, compared to 18 months salary and target bonus for the CFO. These agreements provide continuity in executive leadership and clarify compensation and severance obligations for investors.

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Summary

Key takeaways

Full analysis